ClinicalTrials.gg
CompletedNCT05205811Updated Feb 6, 2026

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

A Phase 3 interventional study of Bupropion and Zonisamide in Smoking Cessation, sponsored by Rose Research Center, LLC. Completed at 2 sites in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Rose Research Center, LLC · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing bupropion in Smoking Cessation — 4 open to participants now, 4 under way, 2 of them phase 3. Bupropion · Smoking Cessation.

Enrollment
24th of 48
180 · median 162
Started
2021
with 2 others
Phase 3
14 of 48
2 open now
Registered
42nd of 48
by date
Lead sponsor
2 of 48
Rose Research Center, LLC

Among the 48 studies testing bupropion in Smoking Cessation, this one is the 24th largest by enrollment, is one of 3 that started in 2021, is one of 14 in phase 3, and was the 42nd registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

4 of the 48 studies testing bupropion in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About bupropion

Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing bupropion in Smoking Cessation, or all of them as a file.
02

Study summary

This three-group randomized double-blind placebo-controlled trial (N=180) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CCs) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline information on the use of combustible cigarettes. All participants enrolled in the study will receive a JUUL e-cigarette at Visit 2 for ad libitum use. After the first week of e-cigarette use (at Visit 3), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with either zonisamide (100 mg daily) or placebo (group 1 and group 2 respectively), or placebo for both medications (group 3) in addition to continued use of the e-cigarette. At each visit, participants will receive enough study drugs (or placebos) and e-cigarettes to last until their next study visit. The combination of zonisamide and bupropion use will continue until Visit 6 (7 weeks of treatment), and e-cigarette use will continue until the end of treatment (Visit 7).

03

Conditions studied

  • Smoking Cessation

Keywords

  • e-cigarette
  • zonisamide
  • bupropion
  • combustible cigarettes
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has signed the ICF and is able to read and understand the information provided in the ICF.
  2. Is 21 to 65 years of age (inclusive) at screening.
  3. Smokes at least 10 commercially available cigarettes per day (no brand restrictions), for the last 12 months.
  4. Has an expired air CO reading of at least 10 ppm at screening.
  5. Is interested in switching to an electronic cigarette.
  6. Is willing and able to comply with the requirements of the study.
  7. Owns a smartphone with text message and data capabilities compatible with necessary surveys.

Exclusion criteria

Exclusion Criteria:

  1. Is unhealthy or cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason) as judged by the Investigator or designated medical staff based on all available assessments from the screening period (e.g., safety laboratory, vital signs, physical examination, , concomitant medications and medical history).
  2. Has a PHQ-9 score greater than 9, or a score greater than 0 on item #9 ("Thoughts that you would be better off dead, or of hurting yourself in some way") at screening.
  3. Has plans to use an FDA-approved smoking cessation product during the study.
  4. Has high blood pressure (systolic > 150 mmHg or diastolic >95 mmHg) at screening.
  5. Has (BMI) less than 15.0 kg/m2 or greater than 40.0 kg/m2.
  6. Has coronary heart disease, structural cardiac disease (including, but not limited to valvular heart disease or cardiac murmurs), cardiac dysrhythmias, syncope, cardiac chest pain, or history of heart attack or heart failure.
  7. Has received psychotherapy or behavioral treatments potentially impacting symptoms of depression, anxiety, or nicotine withdrawal within 30 days of screening, or during the study.
  8. Is taking antidepressants, psychoactive medications (e.g. antipsychotics, benzodiazepines, hypnotics) or medications that prolong .
  9. Has used any of these products in the past 30 days:

    1. Illegal drugs (or if the urine drug screen is positive for cocaine, THC, amphetamines, methamphetamines, or opiates);
    2. Experimental () drugs that are unknown to participant;
    3. Chronic opiate use.
  10. Has used smokeless tobacco (chewing tobacco, snuff), cigars (except for "Black \& Mild" cigars or Cigarillos), pipes, hookah, e-cigarettes, nicotine replacement therapy or other smoking cessation treatments within 14 days of screening.
  11. Has a plan to use an FDA-approved quit-smoking treatment in the next 30 days.
  12. Is pregnant or nursing (by self-report) or has a positive pregnancy test.
  13. Enrollment requirements met.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    Combination zonisamide and bupropion with e-cigarette

    After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with zonisamide (100 mg daily). The combination of zonisamide and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).

    Drug: Bupropion · Drug: Zonisamide · Other: E-cigarette

  • Experimental
    Bupropion with e-cigarette

    After the first week of e-cigarette use (JUUL), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with placebo zonisamide. The combination of placebo and bupropion use will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).

    Drug: Bupropion · Drug: Placebo zonisamide · Other: E-cigarette

  • Placebo comparator
    Placebo with e-cigarette

    After the first week of e-cigarette use (JUUL), participants will be given placebo bupropion with placebo zonisamide. The combination of these placebos will continue for 7 weeks of treatment, and e-cigarette use will continue until the end of the study (an additional 4 weeks).

    Drug: Placebo bupropion · Drug: Placebo zonisamide · Other: E-cigarette

Interventions

  • Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.

    Also known as: Wellbutrin, Zyban

  • Zonisamide (100 mg/daily) for 7 weeks.

    Also known as: zonegran

  • DrugPlacebo bupropion

    Placebo bupropion for 7 weeks.

  • DrugPlacebo zonisamide

    Placebo zonisamide for 7 weeks.

  • OtherE-cigarette

    e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.

    Also known as: JUUL

06

What researchers measure

Primary outcomes

  1. Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by Exhaled carbon monoxide (CO)

    Exhaled carbon monoxide (CO) \< 5 ppm at the end of drug treatment

    Time frame: After 8 weeks

  2. Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by change in Total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)

    Total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)

    Time frame: Baseline, Week 8, Week 12

  3. Complete Switching From Combustible Cigarettes to JUUL e-cigarette as measured by change in self-report of daily cigarette and e-cigarette use

    Self-report of daily cigarette and e-cigarette use

    Time frame: Daily from Week 2 to Week 12

Secondary outcomes

  1. Change in Smoking withdrawal symptoms

    Smoking withdrawal symptoms will be collected using a questionnaire developed by Drs. Shiffman and Jarvik (1976), which assesses craving for cigarettes, negative mood, arousal, missing the habit of smoking, changes in appetite and somatic symptoms and a seven-point scale (from 1-Not at All to 7-Extremely). Higher scores indicate more withdrawal symptoms.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12

  2. Change in Rewarding and aversive effects of smoking and e-cigarette use

    The mCEQ-E will be utilized to assess the degree to which participants experience the reinforcing of smoking, providing five subscale scores: smoking satisfaction (satisfying, tastes good,enjoy smoking), psychological rewards (calms down, more awake, less irritable, helps concentrate, reduces hunger), aversion (dizziness, nauseated), enjoyment of respiratory tract sensations (single-item assessment), craving reduction (single-item assessment). Participants will be asked to assess the 12 items of the questionnaire on a 7-point scale, ranging from "not at all" to "extremely". These 12 items will be asked for the "first cigarette smoked", "cigarette immediately after a meal", and "all other cigarettes." The e-cigarette version of this questionnaire (mECEQ-E) will also be used.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12

Other outcomes

  1. Tolerability of study drugs as measured by frequency of drug termination or drug non-adherence

    The frequency of drug termination or non-adherence prior to Week 8 will be tabulated for each condition. Adverse effects will also be tabulated for each condition, including the following adverse effects of special interest (AESIs): insomnia, agitation, dry mouth, somnolence, headache, nausea, constipation, diarrhea, dizziness or loss of appetite.

    Time frame: Baseline, Week 1, Week 2, Week 4, Week 8

  2. Seven-day point abstinence at 6 months post-switch

    Seven-day point abstinence at 6 months post-switch will be assessed by self-report and confirmed by exhaled carbon monoxide (CO) \< 5 ppm.

    Time frame: 6 Months post Switch Day

07

Study locations

2 sites
  • Rose Research Center
    Charlotte, North Carolina 28262, United States
  • Rose Research Center
    Raleigh, North Carolina 27617, United States
08

References and documents

Publications

  • Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023 May 24;5(5):CD000031. doi: 10.1002/14651858.CD000031.pub6. PubMed 37230961 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Jun 2025, 42 months.

Of 31 phase 3 interventional studies under Smoking Cessation, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 60. This study's 42 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2021
First posted
Jan 25, 2022
StartActual
Dec 14, 2021
Primary completionActual
Jun 19, 2025
CompletionActual
Oct 13, 2025
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05205811
Lead sponsor
Rose Research Center, LLC
Collaborators
Foundation for a Smoke Free World INC
Responsible party
Sponsor
First posted
Jan 25, 2022
Start date
Dec 14, 2021
Primary completion
Jun 19, 2025
Completion
Oct 13, 2025
Last update
Feb 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bupropion · Zonisamide

Start the discussion